Plain-English translation of NCT01241864 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 1 research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether islet transplantation—a procedure where insulin-producing cells from a donor are transplanted into your body—can help people with type 1 diabetes who have already received a kidney transplant achieve better blood sugar control without needing insulin injections. The islet cells come from deceased organ donors and are given through a vein. Researchers want to learn whether this treatment is safe and effective when done together with or shortly after a kidney transplant.
People with type 1 diabetes require insulin shots every day to manage their blood sugar, which can be challenging and doesn't always work perfectly. This trial explores whether transplanting the cells that naturally produce insulin could offer a more normal way to control blood sugar, especially for people who have already undergone kidney transplantation.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive a transplant of islet cells (insulin-producing cells) obtained from a deceased donor, delivered through a vein into your body. The cells will be transplanted either at the time of your kidney transplant or within a few months afterward, depending on the timing of your kidney transplant. You will continue taking medications to prevent rejection of both the kidney and islet cells, and you will have regular follow-up visits to monitor how well the transplant is working and check your blood sugar control.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States